Concord Biotech (NSE:CONCORDBIO) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Debt-to-Asset?

Concord Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹18 Mil. Concord Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹16 Mil. Concord Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was ₹17,643 Mil. Concord Biotech's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

Concord Biotech Debt-to-Asset Historical Data

The historical data trend for Concord Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Debt-to-Asset Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

0.06

0.08

0.05

0.02

0.01

Concord Biotech Quarterly Data
	Mar20	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial							0.02	-	0.01	-	-

Competitive Comparison of Concord Biotech's Debt-to-Asset

For the Biotechnology subindustry, Concord Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Debt-to-Asset falls into.

Concord Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Concord Biotech's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(78.506	+	18.87)	/	17007.085
	=	0.01

Concord Biotech's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(18.169	+	16.067)	/	17643.448
	=	0.00

Concord Biotech (NSE:CONCORDBIO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Concord Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (NSE:CONCORDBIO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

543960:India

Address

Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines